7-101157375-A-G
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001283.5(AP1S1):c.183-2A>G variant causes a splice acceptor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000895 in 1,564,740 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001283.5 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AP1S1 | NM_001283.5 | c.183-2A>G | splice_acceptor_variant | ENST00000337619.11 | NP_001274.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AP1S1 | ENST00000337619.11 | c.183-2A>G | splice_acceptor_variant | 1 | NM_001283.5 | ENSP00000336666 | P4 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152192Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000221 AC: 4AN: 180840Hom.: 0 AF XY: 0.0000104 AC XY: 1AN XY: 96028
GnomAD4 exome AF: 0.00000920 AC: 13AN: 1412548Hom.: 0 Cov.: 31 AF XY: 0.00000859 AC XY: 6AN XY: 698232
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152192Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74356
ClinVar
Submissions by phenotype
MEDNIK syndrome Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 2008 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 01, 2023 | Variant summary: AP1S1 c.183-2A>G is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the 3' canonical splicing acceptor site. These predictions were confirmed by experimental studies and the variant was found to result in alternative splicing (e.g., Montpetit_2008). The variant was found at a frequency of 2.2e-05 in 180840 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.183-2A>G has been reported in the literature in several homozygous individuals affected with MEDNIK syndrome (e.g., Montpetit_2008). This report suggests the variant is very likely to be associated with disease. At least one study has reported experimental evidence demonstrating an impact on protein function, and found that the variant was unable to rescue the mutant phenotype in a zebrafish AP1S1 knockdown model (e.g., Montpetit_2008). The following publication was ascertained in the context of this evaluation (PMID: 19057675). No ClinVar submitters have reported clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. - |
AP1S1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 13, 2024 | The AP1S1 c.183-2A>G variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in the homozygous state in several individuals with MEDNIK syndrome (Reported as IVS2-2A>G in Montpetit et al 2008. PubMed ID: 19057675; Martinelli D et al 2013. PubMed ID: 23423674). This variant is reported in 0.0044% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | This sequence change affects an acceptor splice site in intron 2 of the AP1S1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in AP1S1 are known to be pathogenic (PMID: 19057675). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. Disruption of this splice site has been observed in individual(s) with MEDNIK syndrome (PMID: 19057675, 23423674). It has also been observed to segregate with disease in related individuals. This variant is also known as IVS2-2A>G. ClinVar contains an entry for this variant (Variation ID: 39854). Studies have shown that disruption of this splice site alters AP1S1 gene expression (PMID: 19057675). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at